Trial Profile
A retrospective long-term study to evaluate the outcomes in patients with severe mental disorders receiving long acting injectable risperidone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2016
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Mental disorders; Paranoid disorders; Psychotic disorders; Schizophrenia
- Focus Therapeutic Use
- 06 Nov 2016 New trial record
- 20 Sep 2016 Results presented at the 29th Annual Congress of the European College of Neuropsychopharmacology